Patients with cystic fibrosis (CF) experience significant bone mineral density (BMD) loss at a younger age than those without the disease, with greater decline observed among individuals with ...

Investigators used 3-dimensional quantitative computed tomography to more accurately assess patients’ bone mineral density.

BridgeBio (BBIO) announced that 18-month results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with ...